イチキ　ヨシノブ   ICHIKI Yoshinobu   市来　嘉伸    所属   埼玉医科大学  医学部 国際医療センター　呼吸器外科    職種   専任講師
論文種別	学術雑誌(原著)
言語種別	英語
査読の有無	査読なし
表題	Tumor specific expression of survivin-2B in lung cancer as a novel target of immunotherapy.
掲載誌名	正式名：Lung cancer (Amsterdam, Netherlands) ISSNコード：01695002
巻・号・頁	48(2),281-9頁
著者・共著者	Yoshinobu Ichiki,Takeshi Hanagiri,Mitsuhiro Takenoyama,Tetsuro Baba,Takashi Fukuyama,Yoshika Nagata,Makiko Mizukami,Tetsuya So,Masakazu Sugaya,Manabu Yasuda,Tomoko So,Kenji Sugio,Kosei Yasumoto
発行年月	2005/05
概要	BACKGROUND: Survivin-2B is reported to be specifically expressed in numerous malignant tissues. Furthermore, survivin-2B includes the epitope peptide (survivin-2B(80-88)) which is capable of binding to HLA-A24. In this study, we evaluated whether survivin-2B could be a novel vaccine target against lung cancer. METHOD: (1) The differences in the survivin-2B expression between 15 sets of lung cancer tissues and normal lung tissues were investigated using RT-PCR. (2) The expression of survivin-2B was further examined in 42 lung cancer tissues, and the relationship between the expression and clinicopathologic factors was analyzed. (3) To compare the frequency of precursor CTL between survivin-2B positive and negative lung cancer patients, surivivin-2B(80-88) peptide-specific CTL were induced from regional lymph node lymphocytes (LNL) of four HLA-A24 (+) lung cancer patients, in whom two showed a positive survivin-2B expression of lung cancer while another two were negative, after stimulation with surivivin-2B(80-88). RESULTS: Survivin-2B was specifically expressed in lung cancer tissues, and was expressed in 17 of 42 lung cancer tissues (42.9%). Histologically, it was significantly mor
PMID	15829330